Home
All|
Business |
Technology |
Environment |
Health & Fitness |
Lifestyle |
Entertainment |
Travel |
Politics & Society |
Sports |
RSSMylan’s chief executive Robert Coury has clarified and assured shareholders that the company has not overpaid for the acquisition of Merck. He further added, ‘in this case, by paying for a fairly high quality one-time pristine asset, I am able to...
Related Stories
Most Recent
Most Popular
Most Commented
1
Stars 
(0)
Mylan Laboratories has agreed to acquire the generics business of Merck, of Germany, for $6.6 billion in cash, shooting the US firm into the global top three makers of...
made popular May 14 2007
All Stories
Most Recent
Most Popular
Most Commented
AP, New York
Israeli drugmaker Teva Pharmaceutical says it will buy rival generic drug company Barr Pharmaceuticals for more than $7 billion, in a move to expand its presence in...
made popular Jul 18 2008
AP, New York
A patent dispute over the heartburn drug Protonix escalated Monday when Wyeth said it will sue to recover lost profits from sales of Teva Pharmaceutical Industries...
made popular Dec 24 2007
Mylan Laboratories has agreed to acquire the generics business of Merck, of Germany, for $6.6 billion in cash, shooting the US firm into the global top three makers of...
made popular May 14 2007
Related Tags
Asia Barr Barr Pharmaceuticals Business Eastern European Israel Israeli lawsuit Merck Merger & Acquisition Middle East Mylan New York North America pharma Teva Pharmaceutical U.S. United States Wyeth 